Opus Genetics (IRD) Income from Continuing Operations (2010 - 2026)
Opus Genetics (IRD) reported Income from Continuing Operations of 65535000.0 for Q1 2026, down 699.79% year-over-year from 10926278.1 in Q1 2025, and down 296.63% quarter-over-quarter from 16523000.0 in Q4 2025.
Opus Genetics (IRD) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has 17 years of Income from Continuing Operations data on file, last reported at 65535000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 65535000.0, down 699.79% year-over-year; the trailing twelve-month figure through Mar 2026 was 106932000.0 (down 82.42% YoY), and the FY2025 annual result was 49591000.0, up 13.8% from the prior year.
- Income from Continuing Operations declined to 65535000.0 in Q1 2026 per IRD's latest filing, from 16523000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 33941000.0 in Q4 2022 and troughed at 65535000.0 in Q1 2026.
- A 5-year average of 9691529.41 and a median of 7106000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2026: Income from Continuing Operations surged 637.64% in 2022, then plunged 699.79% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 33941000.0 in 2022, then sank by 114.13% to 4795000.0 in 2023, then sank by 632.74% to 35135000.0 in 2024, then jumped by 52.97% to 16523000.0 in 2025, then sank by 296.63% to 65535000.0 in 2026.
- Business Quant data shows IRD's Income from Continuing Operations at 65535000.0 in Q1 2026, 16523000.0 in Q4 2025, and 17454000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Opus Genetics | 355.39 Mn | 295.43 Mn | - | -65.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.54 Mn |
| Dec 31, 2025 | -16.52 Mn |
| Sep 30, 2025 | -17.45 Mn |
| Jun 30, 2025 | -7.42 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -35.14 Mn |
| Sep 30, 2024 | -7.53 Mn |
| Jun 30, 2024 | -7.77 Mn |
| Mar 31, 2024 | -7.11 Mn |
| Dec 31, 2023 | -4.80 Mn |
| Sep 30, 2023 | 5.56 Mn |
| Jun 30, 2023 | -4.96 Mn |
| Mar 31, 2023 | -5.79 Mn |
| Dec 31, 2022 | 33.94 Mn |
| Sep 30, 2022 | -4.53 Mn |
| Jun 30, 2022 | -4.93 Mn |
| Mar 31, 2022 | -6.60 Mn |
| Dec 31, 2021 | -6.31 Mn |
| Sep 30, 2021 | -4.23 Mn |
| Jun 30, 2021 | -7.14 Mn |